Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Prolonged Remissions After Niv...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma

Bibliographic Details
Main Authors: Roch Houot, Viola Poeschel, Bettina Altmann, Stephanie Angel, Lorenz Thurner, Thomas Illmer, Marc Andre, Martin Dreyling, Hervé Maisonneuve, Hervé Tilly, Stephanie Mayer, Olivier Casasnovas, Steven Le Gouill, Fritz Offner, Guillaume Cartron, Andrea Kerkhoff, Thomas Weber, Joerg Hoffmann, Marita Ziepert, Wolfram Klapper, Emmanuel Itti, Dirk Hellwig, Giorgi Natchkebia, Laurence de Leval, Andreas Rosenwald, Corinne Haioun, Laurent Dercle, Philippe Gaulard, Gerhard Held
Format: Article
Language:English
Published: Wiley 2022-02-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000672
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/HS9.0000000000000672

Similar Items

  • Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA
    by: Marie-Hélène Delfau-Larue, et al.
    Published: (2012-10-01)
  • Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients
    by: Mathilde Lamarque, et al.
    Published: (2016-03-01)
  • Development of research integrity in France is on the rise: the introduction of research integrity officers was a progress
    by: Hervé Maisonneuve
    Published: (2019-10-01)
  • CD30+ lymphoproliferative disorders
    by: Laurence de Leval, et al.
    Published: (2010-10-01)
  • Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial
    by: Nicolas Mounier, et al.
    Published: (2013-11-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs